ArticleiLIVER2023
Intrahepatic cholestasis of pregnancy is associated with increased risk of hepatobiliary disease and adverse fetal outcomes: A systematic review and meta-analysis.
Article in iLIVER, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pregnancies in women with rare diseases: Selected maternal and perinatal outcomes.Acta obstetricia et gynecologica Scandinavica · 2026Article
- ATP-binding Cassette Transporter Defects and Their Roles in Hepatic Diseases.Journal of clinical and translational hepatology · 2026Review
- Management of Recurrent Intrahepatic Cholestasis of Pregnancy: A Case Report.Journal of reproduction & infertility · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: The aim of this study was to review the literature and perform a meta-analysis to clarify the association between intrahepatic cholestasis of pregnancy and risks of long-term maternal hepatobiliary disease as well as adverse fetal outcomes including preterm birth, meconium-stained amniotic fluid, and stillbirth. Methods: This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was performed using Cochrane, Embase, and PubMed databases to identify observational or cohort studies comparing pregnant women with intrahepatic cholestasis of pregnancy (ICP) to pregnant women without ICP. Data from the included studies were analyzed using the Review Manager 5.4.1 software. Results: The meta-analysis showed a significant association between ICP and the risk of hepatobiliary diseases (pooled risk ratio [RR]: 2.81, 95% confidence interval [CI]: 2.66-2.97, Conclusion: ICP demonstrated statistically significant associations with increased risks of hepatobiliary disease, HC, MSAF, and preterm birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.